Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

MAP 2017 – Molecular Analysis for Personalised Therapy

MAP 2017 banner
Start date
13 Oct 2017
End date
14 Oct 2017
Zurich, Switzerland

The advent of genome sequencing is bringing about a quiet revolution in healthcare. Yet while the thirst for advanced genomic knowledge may seem enticing, doctors know that information without interpretation may not be very useful. We are pleased to announce a new high-level scientific meeting that explores ways to better use existing research data in order to improve clinical oncologists’ personalised treatment programs for cancer patients.

The 3rd edition of the Molecular Analysis for Personalised therapy meeting (MAP) was held 13-14 October in Zurich, Switzerland. A joint initiative of Cancer Research UK, UNICANCER and ESMO, this conference shined a light on the latest medical developments in a constantly evolving field.

This meeting is for medical oncologists, interns, academics, regulators, industry R&D reps and investigators and all those interested in discussing the clinical interpretation of molecular tests for metastatic cancers.

View the MAP 2017 programme

Important deadlines



Abstract submission

Until 11 August 2017

Early Bird registration

15 August 2017

Standard registration

2 October 2017


For information regarding registration rates, deadlines and terms and conditions, please see the MAP 2017 website.


Abstract submission is now closed.

Conference Officers & Scientific Committee

Organising Committee

European Society for Medical Oncology
Cancer Research UK
Conference secretariat: Overcome agency

Affiliate Scientific Member

Fondation ARC pour la Recherche sur le Cancer

  • Fabrice André, Institute Gustave Roussy, Villejuif, France
  • Charles Swanton, The Francis Crick Institute, London, UK
  • Jean-Charles Soria, Institute Gustave Roussy, Villejuif, France

Scientific Committee

  • Fabrice André, Institute Gustave Roussy, Villejuif, France (Co-Chair)
  • Jean-Charles Soria, Institute Gustave Roussy, Villejuif, France (Co-Chair)
  • Charlie Swanton, The Francis Crick Institute, London, UK (Co-Chair)
  • Daniel Birnbaum, Centre de Recherche en Cancérologie de Marseille, Marseille, France
  • Jean-Yves Blay, Université Claude Bernard, Lyon, France
  • Carlos Caldas, Cancer Research UK, Cambridge UK
  • Franck Dufour, Fondation ARC pour la recherche sur le cancer, Villejuif, France
  • Christof von Kalle, Universitätsklinikum, Heidelberg, Germany
  • James Larkin, Institute of Cancer Research, London, UK
  • Richard Marais, University of Manchester, UK
  • Serena Nik-Zainal, The Sanger Institute, Cambridge, UK
  • Lillian Siu, University of Toronto, Toronto, Canada
  • Alex Snyder, Memorial Sloan Kettering Cancer Centre, New York, USA
  • Rolf Stahel, University Hospital Zurich, Switzerland
  • Giampaolo Tortora, Universita' degli studi di Verona, Italy

Travel & Accommodation

Accommodation: Rooms were reserved for the participants during the event at preferential rates. For information or booking, contact OVERCOME agency.
Tel: +33 (0)1 41 92 01 20. Email: housing@overcome.fr

Travel: Attractive discounts on a wide range of Air France and KLM worldwide fares were available using event ID code: 29746AF. See here for further information: airfranceklm-globalmeetings.com


3-5, Bd Paul-Emile Victor
92523 Neuilly-sur-Seine Cedex
Tel: +33 (0)1 40 88 97 97
Fax: +33 (0)1 40 88 97 90


This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.